Last reviewed · How we verify
DE-104 ophthalmic solution
DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye.
DE-104 ophthalmic solution is an anti-inflammatory agent that reduces inflammation in the eye. Used for Treatment of non-infectious uveitis affecting the posterior segment of the eye.
At a glance
| Generic name | DE-104 ophthalmic solution |
|---|---|
| Sponsor | Santen Pharmaceutical Co., Ltd. |
| Drug class | Anti-inflammatory agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the production of pro-inflammatory cytokines, thereby reducing the severity of ocular inflammation. This is achieved through its mechanism of action, which is not fully elucidated. Further research is needed to fully understand its mechanism of action.
Approved indications
- Treatment of non-infectious uveitis affecting the posterior segment of the eye
Common side effects
- Eye irritation
Key clinical trials
- Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension (PHASE1, PHASE2)
- Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
- Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DE-104 ophthalmic solution CI brief — competitive landscape report
- DE-104 ophthalmic solution updates RSS · CI watch RSS
- Santen Pharmaceutical Co., Ltd. portfolio CI